Panelists discuss proactive measures that health care teams can implement to manage adverse events associated with Bruton tyrosine kinase (BTK) inhibitors, such as early monitoring, dose adjustments, and supportive care, while emphasizing the importance of patient education to improve adherence and ensure positive treatment outcomes.
What proactive measures can health care teams implement to manage adverse events associated with BTK inhibitors, ensuring both treatment adherence and patient quality of life?
How can oncologists better educate patients about BTK inhibitors to improve adherence and support positive treatment outcomes?